• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ADDF, Charles River collaborate in research award program

ADDF, Charles River collaborate in research award program

July 13, 2011
CenterWatch Staff

The Alzheimer's Drug Discovery Foundation (ADDF) is collaborating with Charles River Laboratories International, a provider of early-stage drug development products and services, to create a new research award program entitled Use of Aged Rats as a Relevant Pre-clinical Model for the Development of Therapies for Cognitive Aging and Alzheimer's Disease.  The program is made possible through a donation from Charles River's Discovery Services business and funds from the ADDF.

The goal of the three-year initiative is to accelerate the discovery of new drugs for cognitive aging and Alzheimer's disease. The program will fund pre-clinical studies focused on proof-of-concept testing of novel compounds in aged rats.  Academic and biotechnology company scientists are invited to apply to the program, which will provide funding of up to $150,000 for one year. The deadline for submissions is Oct. 5, 2011, and funding will be awarded in December 2011. 

Charles River will participate in the grant review process with the ADDF scientific staff and review committee.

"Aging is the leading risk factor for Alzheimer's.  By accelerating research on the relationship between age-related neurodegeneration and cognitive impairment through the use of aged rats, we may uncover and validate novel targets for Alzheimer's disease,” said ADDF's Executive Director Howard Fillit, M.D.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing